Lantern Pharma Provides Q1 2025 Earnings Update

Lantern Pharma (LTRN) reported progress on its clinical trials for LP-184 and LP-300, including enrollment updates and FDA clearances. The company highlighted potential market sizes exceeding $4 billion in metastatic triple-negative breast cancer and over $2 billion in biomarker-defined non-small cell lung cancer.

By Motley Fool Transcribing · Motley Fool · May 21, 2026, 14:19 UTC

Lantern Pharma Provides Q1 2025 Earnings Update

Topics: cancer_treatment drug_development pharmaceuticals

Read the full article at Motley Fool

More World news

Canadian Tire Announces Quarterly Dividend of CAD 1.825 Per Share Seeking Alpha · November 12, 2026, 13:58 UTC
Chicago Atlantic BDC Announces $0.34 Per Share Quarterly Dividend Seeking Alpha · November 12, 2026, 13:59 UTC
William Blair Upgrades AMD to Outperform Amid Leadership Crisis at Nvidia CNBC · November 12, 2026, 13:56 UTC
HawkEye 360 Secures $135 Million in New Global Contracts Seeking Alpha · November 12, 2026, 13:55 UTC
Databento Secures $100 Million Series C Funding at $1.1 Billion Valuation PR Newswire · November 12, 2026, 13:57 UTC
Annex Brands Announces Franchise Renewal for Postal Connections in Fort Mohave, Arizona PR Newswire · November 12, 2026, 13:58 UTC
Nvidia CEO Jensen Huang Resigns Following Personal Scandals and Espionage Allegations The Verge · November 12, 2026, 13:53 UTC
AMD and PsiQuantum Partner to Develop Fault-Tolerant Quantum Computing Infrastructure Seeking Alpha · November 12, 2026, 13:44 UTC
Nvidia CEO Jensen Huang Resigns; CFO Colette Kress Appointed Interim CEO Seeking Alpha · November 12, 2026, 13:50 UTC
Aktis Oncology Reports Q3 Revenue Growth and Significant Increase in Cash Reserves Seeking Alpha · November 12, 2026, 13:50 UTC